UK becomes the first country in Europe to authorize orforglipron

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) authorized orforglipron, sold as Foundayo, on August 10, 2026, making the UK the first country in Europe to approve the GLP-1 tablet for both weight management and type 2 diabetes ^[1]. The authorization was granted to Eli Lilly ^[1].

What the UK label covers

Alongside a reduced-calorie diet and increased physical activity, orforglipron is authorized in the UK for weight loss and weight maintenance in adults with a BMI of 30 or above, or a BMI between 27 and 30 plus at least one weight-related comorbidity ^[1]. It is also authorized to improve blood sugar control in patients with insufficiently controlled type 2 diabetes ^[1].

That two-part label is notable because orforglipron is a pill rather than an injection. Orforglipron is a GLP-1 receptor agonist that mimics glucagon-like peptide-1, a hormone the body releases after eating ^[1]. According to the MHRA, it acts on areas of the brain that regulate appetite, helping people feel fuller for longer, reducing hunger and decreasing food cravings, which can help people eat less ^[1]. In people with type 2 diabetes, it also lowers blood sugar when levels are high ^[1].

Dosing and side effects

The tablet is taken once daily and can be taken at any time of day with no food or water restrictions ^[1]. That is a practical difference from some other oral medicines in this class, which carry timing and fasting rules.

Treatment begins at 0.8 mg and steps up through 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg, with a minimum of one month at each dose level ^[1]. The MHRA says patients should follow the instructions in the Patient Information Leaflet ^[1].

The most common side effects listed by the agency are nausea, constipation, diarrhea, vomiting, dyspepsia (indigestion) and abdominal pain ^[1]. Julian Beach, the MHRA's Executive Director of Healthcare Quality and Access, said the approval followed "rigorous assessment of orforglipron's safety, quality, and effectiveness" and added that, "as with all GLP-1 receptor agonists, this is a prescription-only medication, and the MHRA will keep the safety and effectiveness of orforglipron under close review" ^[1].

Why it matters for patients

A regulatory approval is not the same thing as access. The MHRA states plainly that although the tablet is approved for use in the UK, it is not currently available via the NHS, and that decisions on NHS use will follow established processes including an evaluation by the National Institute for Health and Care Excellence (NICE) ^[1]. In other words, UK patients face a coverage review before the drug becomes routinely available through the public system.

For US readers, the UK decision is mainly a signal about how regulators outside the US are reading the same data package, including the decision to authorize a single oral GLP-1 for both obesity and type 2 diabetes. This source does not describe the US label, US availability, US pricing, or how the UK indications compare with any approval elsewhere, so those comparisons are not established here. The source also does not give trial weight-loss or A1c figures.

The MHRA repeated a warning that applies on both sides of the Atlantic: all GLP-1 medicines are prescription-only and can only be obtained from a registered pharmacy with a prescription from a doctor, and buying them from unregulated sellers carries serious health risks ^[1]. The agency also noted it is against the law in the UK to promote prescription-only medicines directly to the public ^[1].

What happens next

The MHRA said the Summary of Product Characteristics and Patient Information Leaflet would be published on its products website within seven days of the August 10, 2026 approval ^[1]. A NICE evaluation is the next step before NHS availability, and no date for that decision is given in the announcement ^[1]. The agency is encouraging anyone who suspects a side effect to speak with a doctor, pharmacist or nurse and report it through the Yellow Card scheme ^[1].